SARS-CoV-2 Spike Glycoprotein Delta Variant (B.1.617.2, Indian origin) mRNA, with inactivated furin site

Cat #: EG-347

   

Qty   
Product Name SARS-CoV-2 Spike Glycoprotein Delta Variant (B.1.617.2, Indian origin) mRNA, with inactivated furin site
Description

This modified mRNA encodes the full-length SARS-CoV-2 spike glycoprotein B.1.617.2 India origin delta variant, with furin site mutated to PRRD

Features
  • 5' Cap: Capped with ARCA (Anti Reverse Cap Analog, m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG (m7G(5')ppp(5')(2'OMeA)pG, Cap 1)
  • 5’-UTR: derived from human alpha-globin RNA with an optimized Kozak sequence
  • Codon Optimization: Human
  • Mutations: T19R, T95I, G142D, ∆F157+∆R158, E156G, L452R, T478K, D614G, P681R, D950N, P681R, R683A, R685A, D950N
  • Nucleotide Modifications: mRNA modified with both Pseudo-UTP and 5mCTP
  • 3’-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression.
  • PolyA: 180 nt
Sequence Available upon request.
Application Animal Vaccine Research (Not for human use)
Concentration ~1 µg/µl
Transfection Protocol Lipofectamine™ MessengerMAX™ Transfection Reagent Protocol
QC Agarose gel electrophoresis
Shipping Dry ice
Storage -80 oC